Melphalan 140mg/m“2” significantly reduces 5 year progression free survival in multiple myeloma patients receiving a peripheral blood autologous stem cell transplant compared with melphalan 200mg/m“2”

C. Attwood, E. Nicholson,R. Chakraverty,A. Fielding,P. Kottaridis,D. Hughes,A. Mehta, W. Stewart, C. Kyriakou, S. Worthington,S. Grace, A. Wechalekar, S. MacKinnon

Clinical Lymphoma, Myeloma & Leukemia(2015)

引用 0|浏览16
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要